Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient’s treatment and enable physicians to provide a more accurate prognosis.
The study, published online this month by Breast Cancer Research and Treatment, established that levels of GRB7, or growth factor receptor bound protein seven, are important on their own as a marker for aggressive breast cancer. Previously it was understood that patients whose breast cancer tumors tested positive for high levels of HER-2, the protein human epidermal growth factor receptor-2, tended to have a more aggressive form of the disease than patients whose tumors did not have elevated levels of this protein. However, OHSU Knight Cancer Institute researchers found that the protein driving this aggressive form of the disease is GRB7 rather than HER-2 on its own.
“Our work shows GRB7 protein levels are an important and independent factor in determining a prognosis for breast cancer,” said OHSU Knight Cancer Institute member Shiuh-Wen Luoh, M.D., Ph.D., assistant professor of medicine in the Division of Hematology and Medical Oncology, medical oncology director for the Comprehensive Breast Cancer Clinic and senior author of the paper.
The findings could have implications for the types of therapies used. Luoh said a next step will be to determine if high levels of the GRB7 protein influence patient responses to anti-HER-2 therapies such as Herceptin or Tykerb.
The research into GRB7’s role is advancing the OHSU Knight Cancer Institute’s mission to provide cancer patients with personalized treatments that target the specific characteristics of their disease.
“Our work was only made possible with the availability of a breast tumor repository that OHSU and the Knight Cancer Institute began collecting about 20 years ago,” said Ed Keenan, Ph.D., who served as co-investigator on the study. Keenan, former associate dean of medical education for OHSU’s School of Medicine, is a professor in the Department of Physiology and Pharmacology and the Department of Surgery. He also serves as president of The Foundation for Medical Excellence.
Other researchers who worked on the paper, titled “GRB7 protein over-expression and clinical outcome in breast cancer,” were Betsy Ramsey, B.S., research associate, OHSU Knight Cancer Institute and Department of Physiology and Pharmacology; Tao Bai, B.S., research associate, Division of Hematology and Medical Oncology; Amy E. Hanlon Newell, Ph.D., senior research associate, Department of Molecular and Medical Genetics; Megan Troxell, M.D, Ph.D., associate professor, Department of Pathology; Byung S. Park, Ph.D., research assistant professor, Division of Biostatistics, Department of Public Health and Preventive Medicine; and Susan B. Olson, Ph.D., FACMG, professor, Department of Molecular and Medical Genetics and director of the Clinical & Research Cytogenetics Laboratories.
The study was funded by the Department of Veterans Affairs, Portland VA Research Foundation, OHSU Presidential Bridge Award and OHSU Foundation.
About OHSU Knight Cancer Institute
With the latest treatments, technologies, hundreds of research studies and about 400 clinical trials, the OHSU Knight Cancer Institute is the only cancer center between Sacramento and Seattle designated by the National Cancer Institute — an honor earned only by the nation's top cancer centers. The honor is shared among the more than 650 doctors, nurses, scientists and staff who work together at the OHSU Knight Cancer Institute to reduce the impact of cancer. Visit www.ohsuhealth.com/cancer.
Oregon Health & Science University is the state’s only health and research university, and Oregon’s only academic health center. OHSU is Portland's largest employer and the fourth largest in Oregon (excluding government). OHSU's size contributes to its ability to provide many services and community support activities not found anywhere else in the state. It serves patients from every corner of the state, and is a conduit for learning for more than 3,400 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to every county in the state.